ErbB-directed immunotherapy: antibodies in current practice and promising new agents

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• The ErbB family (ErbB1, ErbB2) plays a critical role in oncogenesis and serves as a prognostic marker in various cancers.
• Selective expression of ErbB proteins on tumor cells enables targeted therapies like kinase inhibitors and therapeutic antibodies.
• Trastuzumab, an FDA-approved humanized antibody, pioneered ErbB-targeted therapy for solid tumors.

Purpose of the Study:

• To review the biological and clinical basis of ErbB-targeted therapies.
• To describe key antibodies targeting ErbB1 and ErbB2 currently in clinical trials or approved.
• To discuss antibody conjugation, engineering strategies, and clinical resistance.

Main Methods:

• Review of scientific literature on ErbB-targeting antibodies.
• Analysis of clinical trial data and FDA approvals for ErbB-targeting agents.
• Discussion of antibody conjugation and engineering techniques.

Main Results:

• Numerous humanized antibodies targeting ErbB1 and ErbB2 are in clinical development or approved.
• Antibody-drug conjugates and engineered variants demonstrate improved therapeutic efficacy and broader applicability.
• Strategies include radioactive isotopes, cytotoxic agents, liposomes, and novel antibody derivatives.

Conclusions:

• ErbB-targeted antibodies represent a significant advancement in cancer therapy.
• Ongoing research focuses on enhancing antibody efficacy, overcoming resistance, and expanding patient populations.
• Innovative conjugation and engineering strategies are crucial for future therapeutic development.